My UNVC strategy for future profits and investing:
My UNVC strategy for future profits and investing:
Right now I only have only one stock in my portfolio (UNVC) -because I sold everything to buy as many UNVC shares as I could. So my investment portfolio can hardly be called diversified at this point.
But here’s my 2021 strategy to change that:
1) After UNVC goes to the NASDAQ: In the beginning, I will take only the money that I really need (at different points during the year) -to pay off credit card and other debts, to get $$ for an emergency fund, $$ or health care (if needed) and/or money to live on) In the beginning, no fancy cars or other big ticket items for me, -only what I need for daily life!
2) Throughout 2021 I will be watching Biden’s tax moves carefully. Right now he’s too busy with the pandemic and other problems. But towards the middle to the end of 2021 I suspect he will try to implement his proposed tax changes (for 2022). IMO the most important part of Biden’s tax program is his proposed tax on long-term capital gains for profits over $1 million (43.4%, -taxed as regular income).
If that is implemented, I will wait until sometime in December of this year, to sell 1/4 to 1/2 of my UNVC shares (but always keeping some shares long-term).
3) Why? By waiting until December of 2021 I can most likely get the highest prices for my UNVC shares vs. selling earlier in the year. IF Biden’s higher (43.4% for profits over $1 million) capital gains taxes are in effect for 2022 then I will take millions of dollars in UNVC profits in December 2021. That way my maximum long-term capital gains rate will be 23.8%. I never want to pay 43.4% in taxes, and 2021 will be my last chance to reap big profits in order to diversity my portfolio. If there are no tax changes for 2022, then I can wait and sell shares for higher prices in 2022.
4) After selling, I will transfer the millions in cash (as well as some or all my remaining UNVC stock) to Vanguard (see bogleheads.org). At Vanguard, I will invest in 3-5 low-cost Vanguard index funds as well as Vanguard ETF’s. and some big board stocks, - in order to begin to diversify my investments.
IMO Vanguard is the way to go because of their great investment products and very low fees/cost.
So IMO there is no need to a pay a fancy (and expensive) financial advisor or private banker 1-2% of your assets per year for advice!
2
Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....
Continue Reading
Top 5 Most Recently Viewed Articles
Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...
Continue Reading
Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...
Continue Reading
Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...
Continue Reading
Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...
Continue Reading
Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...
Continue Reading